Oryon Cell Therapies Appoints Burkhard Blank, M.D., as Chief Medical Officer [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
BELMONT, Mass., April 15, 2026 BUSINESS WIRE )--Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, today announced the appointment of Burkhard Blank, M.D., as Chief Medical Officer (CMO). Dr. Blank is an accomplished biopharmaceutical leader with decades of experience spanning clinical development, regulatory strategy, medical affairs and pharmaceutical operations across a broad range of therapeutic areas, including neurology. He has led global development programs from early-stage research through regulatory approval, including eight NDA and corresponding MAA submissions, all resulting in market approvals. "Burkhard is a highly accomplished drug developer whose experience spans the full arc of bringing innovative therapies from concept to approval," said Ron Cohen, M.D., Chief Executive Officer of Oryon. "During his tenure as CMO at Aco
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind (MNKD) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- MannKind (MNKD) was given a new $8.00 price target by Mizuho.MarketBeat
- Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy? [Yahoo! Finance]Yahoo! Finance
- How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential [Yahoo! Finance]Yahoo! Finance
- MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) [Seeking Alpha]Seeking Alpha
MNKD
Earnings
- 2/26/26 - Beat
MNKD
Sec Filings
- 4/7/26 - Form ARS
- 4/7/26 - Form DEFA14A
- 4/7/26 - Form DEF
- MNKD's page on the SEC website